This study evaluates the cost-effectiveness and budget impact to US payers of point-of-care nucleic acid amplification tests (NAAT) for group A streptococcus. Objectives: In the United States, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback